Recent Stories
Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: RobotsBlack October Wasn't an Attack Wave. It Was a Warning.Extreme Ownership Means Ultimate Achievement – NASA Culture Shift
← Back to the board
Money

NIH awarded Blacksmith Medicines contract 75N93022C00060 for development of FG-2101, an LpxC inhibitor for MDR gram-negative urinary tract infections.

Why it’s here: NIH award funding development of a novel first-in-class antibiotic for drug-resistant infections, a biotechnology program with federal funding ties in the Biotechnology area.

Trace across the board

Item

Connected

17 links

About

  • National Institutes of Health
  • Department of Health and Human Services

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy